Kanagawa, Japan, 27, Mar. 2024 – FIMECS, Inc. (“FIMECS”) a private biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the appointment of Katsuhiro Uto, Ph.D., effective as of 26, Mar. 2024, to the role of an Outside Director. He has 19 years of experience in a drug discovery field and 2 years of industry experience in the listed company as a board of director. Kosuke Ishii was also newly appointed as an outside audit & supervisory board member on the day. He is a certified public accountant and has experience in an auditing firm. He also has industry experiences in the listed and private companies as a head of general administration and a board of director. They have valuable experiences that FIMECS needs and expect to contribute to the growth of FIMECS.
Outside board of directors, Tomokazu Saito, Yusuke Miyazaki and Mikio Kawahara, and outside audit & supervisory board members, Yoshiyuki Jojima, Kenji Maekawa and Yoichi Yamagishi have been resigned on the day.
About FIMECS, Inc.
FIMECS, Inc. is developing a new class of drugs based on targeted protein degradation for the currently ‘undruggable’ targets in immuno-oncology and oncology areas. The company became able to discover drug candidates for inducing the degradation of disease-relevant targeted proteins by integrating proprietary E3 ligase binders and RaPPIDS™ platform. This drug discovery platform will help providing drugs to the patients all over the world through various internal and collaboration projects. https://www.fimecs.com/eng/
# # #
Contact:
FIMECS, Inc.
26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan
Tel: +81-466-96-0261
Email: info@fimecs.com